Betting on continued recovery for Harpoon. HARPWe are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistic
−8.71USD
−67.731MUSD
31.915MUSD
13.411M
About Harpoon Therapeutics, Inc.
Sector
Industry
CEO
Julia Marie Eastland
Website
Headquarters
South San Francisco
Employees (FY)
50
Founded
2015
ISIN
US41358P2056
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.
HARP: 92% of shares belong to insiders or institutions!Amazing things happen when almost all of the supply of shares is "off limits" to market participants. I've seen this before in other companies prior to COVID stock meltdown, where insiders continually buy their own stock until more than 90% of it is in their control. After this period of buying, the
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
